liftsiron
Owner/Admin
- Joined
- Nov 12, 2003
- Messages
- 18,979
Using High-Dose Omega-3 Fatty Acid Supplements to Lower Triglyceride Levels in 10- to 19-Year-Olds
Show all authors
Sarah D. de Ferranti, MD, MPH, Carly E. Milliren, MPH, Erica R. Denhoff, MPH, ...
First Published April 4, 2014 Research Article Find in PubMed
https://doi.org/10.1177/0009922814528032
Article information
Abstract
Background. Omega-3 fatty acids supplements lower triglyceride (TG) levels in adults; little pediatric information is available. We evaluated their effect in hypertriglyceridemic adolescents. Methods. Twenty-five patients aged 10 to 19 years with TG levels 150 to 1000 mg/dL were randomized to 6 months double-blind trial of Lovaza (~3360 mg docosahexaenoic acid + eicosapentaenoic acid per day) versus placebo. Results. Baseline mean TG levels were 227 mg/dL (standard deviation = 49). TG levels declined at 3 months in the Lovaza group by 54 ? 27 mg/dL (mean ? standard error; P = .02) and by 34 ? 26 mg/dL (P = .16) in the placebo group. The difference in TG lowering between groups was not significant (P = .52). There were no between-group differences in endothelial function, blood pressure, body mass index, C-reactive protein, or side effects. Conclusions. High-dose omega-3 fatty acid supplements are well tolerated in adolescents. However, declines in TG levels did not differ significantly from Placebo in this small study.
Show all authors
Sarah D. de Ferranti, MD, MPH, Carly E. Milliren, MPH, Erica R. Denhoff, MPH, ...
First Published April 4, 2014 Research Article Find in PubMed
https://doi.org/10.1177/0009922814528032
Article information
Abstract
Background. Omega-3 fatty acids supplements lower triglyceride (TG) levels in adults; little pediatric information is available. We evaluated their effect in hypertriglyceridemic adolescents. Methods. Twenty-five patients aged 10 to 19 years with TG levels 150 to 1000 mg/dL were randomized to 6 months double-blind trial of Lovaza (~3360 mg docosahexaenoic acid + eicosapentaenoic acid per day) versus placebo. Results. Baseline mean TG levels were 227 mg/dL (standard deviation = 49). TG levels declined at 3 months in the Lovaza group by 54 ? 27 mg/dL (mean ? standard error; P = .02) and by 34 ? 26 mg/dL (P = .16) in the placebo group. The difference in TG lowering between groups was not significant (P = .52). There were no between-group differences in endothelial function, blood pressure, body mass index, C-reactive protein, or side effects. Conclusions. High-dose omega-3 fatty acid supplements are well tolerated in adolescents. However, declines in TG levels did not differ significantly from Placebo in this small study.
